InvestorsHub Logo
Followers 58
Posts 3964
Boards Moderated 0
Alias Born 04/23/2013

Re: DMC8 post# 423980

Monday, 05/06/2024 9:47:09 AM

Monday, May 06, 2024 9:47:09 AM

Post# of 426557
Thanks for the post. Here's a recap + ClinicalTrials.gov website:
$AMRN More info on the Taiwan RCT to reduce migraine frequency & severity with high dose EPA (EPADEL):
Here is the Peer Reviewed Publication:

https://www.sciencedirect.com/science/article/pii/S0889159124003003?via%3Dihub
Here’s the ClinicalTrials website:

https://classic.clinicaltrials.gov/ct2/show/NCT04572789

The primary outcome was the decrease in migraine attacks over a 12-week period & the severity. Several Secondary Outcomes are listed in the publication.
It appears that many Outcome measures were met with significance including the Primary:
Comparing baseline values to those at week 12, the EPA group displayed significant improvements in various parameters within the group, including a marked reduction in monthly migraine frequency (7.4 ± 5.0 days vs. 3.0 ± 2.0 days, p < 0.0001), decreased usage of acute headache medication (2.9 ± 3.2 days vs. 1.6 ± 1.7 days, p = 0.013), lowered headache severity (VAS score: 5.5 ± 2.0 vs. 4.2 ± 2.6, p = 0.004),
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News